PLA2R抗体与原发性膜性肾病临床结局的时间关联
本研究纳入30例接受免疫抑制治疗的原发性膜性肾病(PMN)且aPLA2R升高的患者,每月检测血清aPLA2R并收集临床资料。结果显示80%患者6个月内达到血清学缓解,67%达到临床缓解,血清学缓解早于临床缓解,治疗结束时aPLA2R持续阳性与临床抵抗相关。
要点
- aPLA2R下降先于临床缓解,血清学与临床缓解中位时间分别为2.7和5.05个月。
- 治疗6个月时80%患者达血清学缓解,67%达临床缓解。
- 治疗结束时aPLA2R持续阳性与临床抵抗相关。
核心结论
- 在aPLA2R相关PMN患者中,循环aPLA2R下降先于临床缓解,治疗结束时aPLA2R持续存在与临床抵抗相关。
研究设计与样本
- 基线及之后6个月每月检测血清aPLA2R,临床资料收集9个月。
- 血清学缓解定义为连续2次样本aPLA2R阴性,临床缓解采用标准标准。
主要发现
- 30例中28例(93%)基线aPLA2R升高,2例(7%)1个月后转阳。
- 平均年龄33.2±1岁(范围13-52),基线aPLA2R中位滴度163.41(范围70-291.01)RU/ml。
- 24例(80%)在6个月内达到血清学缓解,其中54%在第一个月结束时aPLA2R转阴。
- 20例(67%)达到临床缓解,血清学和临床缓解时间分别为2.7±1.71和5.05±2.64个月。
临床怎么用
- 监测aPLA2R动态有助于预测PMN治疗反应,血清学缓解可早于临床缓解。
- 治疗结束时aPLA2R持续阳性提示临床抵抗可能,需考虑调整治疗。
局限性
- 单中心小样本研究(30例),随访时间有限(临床资料9个月)。
- 血清学缓解定义基于连续2次阴性,未报告检测方法细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Autoantibodies to M-type phospholipase A2 receptor (aPLA2R) are seen in two-thirds of patients with primary membranous nephropathy (PMN) and are associated with disease activity. However, the precise temporal dynamics between the presence and amount of aPLA2R in circulation, as well as the clinical activity, are not known. We evaluated the temporal association between disease activity and serum aPLA2R during and after treatment in PMN. METHODS: The study included all patients with PMN and elevated aPLA2R who were started on immunosuppressive therapy for persistent nephrotic syndrome at a single center between December 2014 and December 2015. Serum samples were tested for aPLA2R at baseline and at monthly intervals for 6 months. Clinical details were collected monthly for 9 months. Serological remission was defined as negative aPLA2R in 2 consecutive samples. Clinical remission was defined by standard criteria. RESULTS: A total of 30 patients with PMN were studied. Of these, 28 (93%) had elevated levels at baseline, whereas 2 (7%) became positive after 1 month. The mean age was 33.2 ± 1 (range, 13-52) years. Median baseline aPLA2R titer was 163.41 (range, 70-291.01) RU/ml. A total of 24 patients (80%) achieved serological remission by 6 months. Among all the serological responders, 54% had achieved negative aPLA2R by the end of the first month. Clinical remission was observed in 20 patients (67%). Serological and clinical remission were noted at 2.7 ± 1.71 and 5.05 ± 2.64 months, respectively. CONCLUSION: In patients with aPLA2R-associated PMN, reduction in circulating aPLA2R precedes clinical remission. Persistence of aPLA2R at the end of therapy is associated with clinical resistance.
引用
- Ramachandran R, Yadav AK, Kumar V, et al. Temporal Association Between PLA2R Antibodies and Clinical Outcomes in Primary Membranous Nephropathy. Kidney Int Rep. 2017. PMID: 29340324. doi:10.1016/j.ekir.2017.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。